Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...
2don MSN
Switch off your allergies for years without daily pills? Know the treatment backed by WHO and AAAAI
Allergy shots and drops offer a transformative solution for millions. Major health organisations globally endorse this ...
If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...
Winter woes like blocked noses and breathing trouble for asthma and sinus sufferers may find relief with turmeric. Its potent ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...
ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...
A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...
Major advancements in pulmonary fibrosis treatment and critical warnings regarding both indoor air quality and scientific ...
FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback